Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart…
New survey results show health systems starting to recover from pandemic After three years of the COVID-19 pandemic, health systems in countries have started showing the first major signs of health system recovery, according to the WHO interim report on the…
African Parliamentarians rally to boost life-saving laws, regulations on road safety Parliamentarians, policy-makers and experts from 10 African countries met today to strengthen laws and actions to curb the scourge of road crash deaths. The Network of African Road Safety…
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from…
Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines Despite successful efforts to control meningitis in several regions of the world, it continues to be a…
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the…
Lilly’s tripeptide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to…
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc. Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.…
REGENERON AND ALNYLAM REPORT POSITIVE INTERIM PHASE 1 CLINICAL DATA ON ALN-APP, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ALZHEIMER’S DISEASE AND CEREBRAL AMYLOID ANGIOPATHY Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose…
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients Novartis today announced detailed results from the Phase III APPOINT-PNH trial of investigational oral monotherapy iptacopan…
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based…